BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 2020;267:1991-2001. [PMID: 32189108 DOI: 10.1007/s00415-020-09770-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr; REGAIN Study Group. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology 2021;96:e610-8. [PMID: 33229455 DOI: 10.1212/WNL.0000000000011207] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve 2021;64:662-9. [PMID: 34590717 DOI: 10.1002/mus.27422] [Reference Citation Analysis]
3 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Reference Citation Analysis]
4 Albazli K, Kaminski HJ, Howard JF Jr. Complement Inhibitor Therapy for Myasthenia Gravis. Front Immunol 2020;11:917. [PMID: 32582144 DOI: 10.3389/fimmu.2020.00917] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol 2020;11:538. [PMID: 32714266 DOI: 10.3389/fneur.2020.00538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhao R, Wang Y, Huan X, Zhong H, Zhou Z, Xi J, Da Y, Lei L, Chang T, Ruan Z, Luo L, Li S, Yang H, Li Y, Luo S, Zhao C. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis. J Transl Med 2021;19:285. [PMID: 34193193 DOI: 10.1186/s12967-021-02961-9] [Reference Citation Analysis]
7 Mantegazza R, Cavalcante P. Eculizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther 2020;20:991-8. [PMID: 32602752 DOI: 10.1080/14712598.2020.1786530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 2022. [PMID: 34989427 DOI: 10.1002/mus.27476] [Reference Citation Analysis]
9 Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Front Neurol 2021;12:696385. [PMID: 34795626 DOI: 10.3389/fneur.2021.696385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]